Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey.

Journal: Clinical genitourinary cancer
PMID: 26775721

Abstract

BACKGROUND: The administration of carboplatin AUC 7 has become a standard adjuvant option for patients undergoing orchiectomy for stage I seminoma, in alternative to radiotherapy on retroperitoneal lymphnodes or surveillance. The toxicity of AUC 7 carboplatin appeared manageable in the pivotal trial of Oliver et al, but dose ranges were not reported. Fear of toxicity may induce arbitrary dose reductions, which may potentially compromise patients' outcome.

Authors

  • Alberto Diminutto
    Istituto Oncologico Veneto IOV IRCCS, Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Padova, Italy.
  • Umberto Basso
    Istituto Oncologico Veneto IOV IRCCS, Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Padova, Italy. Electronic address: umberto.basso@ioveneto.it.
  • Marco Maruzzo
    Istituto Oncologico Veneto IOV IRCCS, Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Padova, Italy.
  • Franco Morelli
    Casa Sollievo della Sofferenza IRCCS, Medical Oncology Department, Foggia, Italy.
  • Ugo De Giorgi
    IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Medical Oncology Department, Forlì-Cesena, Italy.
  • Alessandra Perin
    Azienda ULSS 4 Alto Vicentino, Medical Oncology Department, Vicenza, Italy.
  • Anna Paola Fraccon
    Casa di Cura Polispecialistica Dott. Pederzoli, Medical Oncology Department, Verona, Italy.
  • Giovanni Lo Re
    Ospedale Santa Maria Degli Angeli, Medical Oncology Department, Pordenone, Italy.
  • Anna Rizzi
    Fondazione Poliambulanza - Istituto Ospedaliero, Medical Oncology Department, Brescia, Italy.
  • Teodoro Sava
    Azienda Ospedaliera Universitaria Integrata Verona, Medical Oncology Department, Verona, Italy.
  • Giuseppe Fornarini
    IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Medical Oncology Department, Genova, Italy.
  • Francesca Valcamonico
    Spedali Civili di Brescia, Medical Oncology Department, Brescia, Italy.
  • Fable Zustovich
    Istituto Oncologico Veneto IOV IRCCS, Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Padova, Italy.
  • Francesco Massari
    Azienda Ospedaliera Universitaria Integrata Verona, Medical Oncology Department, Verona, Italy.
  • Elisa Zanardi
    Istituto Oncologico Veneto IOV IRCCS, Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Padova, Italy.
  • Anna Roma
    Istituto Oncologico Veneto IOV IRCCS, Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Padova, Italy.
  • Filiberto Zattoni
    Urology Clinic, Department of Surgical, Oncological and Gastroenterological Sciences, Padova, Italy.
  • Vittorina Zagonel
    Istituto Oncologico Veneto IOV IRCCS, Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Padova, Italy.

Keywords

External Resources

Popular Topics
Recent Journals